- Revenue from operations at Rs 2,101Cr, up 15.7% YoY
- EBITDA margins at 19.2% with EBITDA up 20.1% YoY
- PAT at 215Cr, up 41% YoY
- Domestic business sales at 995Cr, up 9.4% YoY
- International business sales at 1,106Cr, up 22.1% YoY
Bengaluru : Emcure Pharmaceuticals (BSE:544210, NSE: EMCURE) today announced its consolidated financial results for the quarter ended June 30th, 2025.
The quarter saw robust performance from both Domestic and International businesses. Emcure’s International business grew 22% with all businesses performing. Rest of the World business continued the healthy momentum growing 42%. Company’s Canada business grew 16.4% led by new launches and market share gains. Europe saw early benefits of new launches and grew 12.8%.
Domestic business grew 9.4% led by strong performance in all out key therapies and aided by new initiatives in Derma and OTC. During the quarter, the company further strengthened its domestic business through expansion of its strategic partnership with Sanofi. Going forward, Emcure will be marketing and distributing Sanofi’s Oral Anti-diabetic portfolio in addition to the cardiovascular portfolio.
Commenting on the results, Satish Mehta, CEO and Managing Director, Emcure Pharmaceuticals Ltd., said, “We delivered robust performance across all businesses in Q1. We continue to augment our portfolio in all our focus markets though in-licensing and in-house development. The expanded Sanofi partnership positions us well in the fast-growing metabolic segment. We also have a strong product pipeline for both our domestic and international markets which will fuel future growth. We remain focused on improving efficiencies to drive sustained improvement in margins. ”
Revenue break-up:
| Rs Cr | 1Q26 | 1Q25 | YOY% | 4Q25 | QOQ% |
| Revenue from operations | 2,101 | 1,815 | 15.7% | 2,116 | -0.7% |
| Domestic | 995 | 909 | 9.4% | 929 | 7.1% |
| International | 1,106 | 906 | 22.1% | 1,187 | -6.9% |
| EM | 360 | 254 | 41.9% | 481 | -25.1% |
| EU | 403 | 358 | 12.8% | 396 | 1.9% |
| CA | 342 | 294 | 16.4% | 310 | 10.1% |
Contd.
Performance Summary (Consolidated)
| Rs Cr | 1Q26 | 1Q25 | YOY% | 4Q25 | QOQ% |
| Revenue from operations | 2,101 | 1,815 | 15.72% | 2,116 | -0.74% |
| Material Cost | 802 | 683 | 17.41% | 892 | -10.10% |
| Gross Profit | 1,299 | 1,132 | 14.71% | 1,224 | 6.08% |
| Gross Profit Margins | 61.8% | 62.4% | 57.8% | ||
| Employee Costs | 393 | 350 | 12.29% | 373 | 5.39% |
| Other expenses | 501 | 445 | 12.54% | 461 | 8.75% |
| EBITDA | 404 | 336 | 20.09% | 390 | 3.58% |
| EBITDA Margins | 19.23% | 18.53% | 18.43% | ||
| Other Income | 4 | 23 | 4 | ||
| Depreciation and Amortisation | 99 | 94 | 97 | ||
| Finance Costs inc. Forex | 14 | 59 | 26 | ||
| Exceptional Items | 4 | 0 | 10 | ||
| Profit Before Tax (PBT) | 291 | 207 | 40.19% | 261 | 11.57% |
| Tax | 76 | 55 | 63 | ||
| Profit After Tax (PAT) | 215 | 153 | 40.76% | 197 | 8.90% |
| PAT Margins | 10.2% | 8.4% | 9.3% |
Leave a Reply